Inactive Instrument

Analyst Reco. Horizon Pharma Inc Nasdaq

Equities

US44047T1097

End-of-day quote Nasdaq Other stock markets
- ^USD	-

01-16	Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders	CI
2023	Global markets live: Boeing, Amgen, Microsoft, Volkswagen, Tesla...

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UBS Adjusts Horizon Therapeutics Price Target to $116.50 From $76, Maintains Neutral Rating	13/12/22	MT
BMO Capital Downgrades Horizon Therapeutics to Market Perform From Outperform With $117 Price Target	13/12/22	MT
Guggenheim Downgrades Horizon Therapeutics to Neutral From Buy, Adjusts Price Target to $116.50 From $98	13/12/22	MT
SVB Securities Downgrades Horizon Therapeutics to Market Perform From Outperform, Adjusts Price Target to $116.50 From $88	13/12/22	MT
Wells Fargo Downgrades Horizon Therapeutics to Equalweight From Overweight, Adjusts Price Target to $116.50 From $118	13/12/22	MT
Piper Sandler Raises Price Target on Horizon Therapeutics to $110 From $90, Maintains Overweight Rating	07/12/22	MT
SVB Securities Adjusts Horizon Therapeutics' Price Target to $88 From $80, Keeps Outperform Rating	03/11/22	MT
UBS Adjusts Horizon Therapeutics Price Target to $76 From $71, Maintains Neutral Rating	03/11/22	MT
Oppenheimer Adjusts Horizon Therapeutics Price Target to $92 From $90, Maintains Outperform Rating	03/11/22	MT
HC Wainwright Starts Horizon Therapeutics at Neutral With $74 Price Target	01/11/22	MT
Piper Sandler Adjusts Horizon Therapeutics' Price Target to $88 From $90, Maintains Overweight Rating	25/10/22	MT
UBS Downgrades Horizon Therapeutics to Neutral From Buy, Adjusts Price Target to $71 From $137	04/08/22	MT
Morgan Stanley Lowers Horizon Therapeutics Price Target to $90 From $135, Maintains Overweight Rating	04/08/22	MT
BMO Capital Adjusts Price Target on Horizon Therapeutics to $117 From $145, Keeps Outperform Rating	04/08/22	MT
Goldman Sachs Adjusts Price Target on Horizon Therapeutics to $144 From $164, Reiterates Buy Rating	04/08/22	MT
Oppenheimer Adjusts Horizon Therapeutics' Price Target to $91 From $140, Maintains Outperform Rating	04/08/22	MT
SVB Leerink Upgrades Horizon Therapeutics to Outperform from Market Perform, Adjusts Price Target to $80 from $95	04/08/22	MT
Stifel Adjusts Price Target on Horizon Therapeutics to $138 From $140, Reiterates Buy Rating	04/08/22	MT
UBS Lowers Horizon Therapeutics' Price Target to $137 From $139, Maintains Buy Rating	05/07/22	MT
UBS Initiates Coverage on Horizon Therapeutics With Buy Rating, $139 Price Target	14/06/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Horizon Pharma Inc Nasdaq

Equities

US44047T1097

Analyst Reco.

Filters